UT Health San Antonio (Long School of Medicine)
Radiation Oncology residency · San Antonio, TX · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The University of Texas at San Antonio Health Science Center's research in radiation oncology, which the program shares with other departments and affiliated hospitals.
About The University of Texas at San Antonio Health Science Centerinstitution-wide radiation oncology research
Radiation Oncology publications from The University of Texas at San Antonio Health Science Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
102
works per year
35th of 47 radiation oncology residency programs
+2.0%
2-year growth
40th of 47 radiation oncology residency programs
23.6%
in top 10% of field (works before 2025)
16th of 47 radiation oncology residency programs
37.2%
cited above world average
38th of 47 radiation oncology residency programs
Works per year · * 2026 so far
Oncology · 374Radiology, Nuclear Medicine and Imaging · 106
Radiation Oncology research topics at The University of Texas at San Antonio Health Science Center
Papers in the window; each links to the list on OpenAlex.
- Cancer Immunotherapy and Biomarkers 66
- Cancer survivorship and care 42
- Pancreatic and Hepatic Oncology Research 33
- Cutaneous Melanoma Detection and Management 25
- COVID-19 and healthcare impacts 19
- Global Cancer Incidence and Screening 18
- Colorectal Cancer Screening and Detection 17
- Glioma Diagnosis and Treatment 15
Most cited at The University of Texas at San Antonio Health Science Center since 2024
All radiation oncology papers there on OpenAlex
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber et al. · The Lancet · 2024 · PubMed · cited 958
- Screening for Breast CancerUS Preventive Services Task Force et al. · JAMA · 2024 · PubMed · cited 510
- Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trialAndrea J. Bullock et al. · Nature Medicine · 2024 · PubMed · cited 159
- SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam Grippin et al. · Nature · 2025 · PubMed · cited 151
- Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical SubgroupsAditya Bardia et al. · Clinical Cancer Research · 2024 · PubMed · cited 124
- Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialAlexander Gerhard Miethke et al. · The Lancet. Gastroenterology & hepatology · 2024 · PubMed · cited 78
- The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunitiesHeng‐Chung Kung et al. · Nature Reviews Clinical Oncology · 2025 · PubMed · cited 72
- Clinical development of immuno-oncology therapeuticsJianxin Wang et al. · Cancer Letters · 2025 · PubMed · cited 57
- The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and InflammasomesAtef M. Erasha et al. · International Journal of Molecular Sciences · 2025 · PubMed · cited 49
- Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy responseNasim Ebrahimi et al. · Cancer and Metastasis Reviews · 2024 · PubMed · cited 49